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This review describes recent developments from our laboratory involving the synthesis of the
structurally complex, pyrazinone-containing dragmacidin alkaloids.
Introduction
Over the past several decades, the search for natural products
in marine and terrestrial environments has led to the discovery
of a number of biologically active bis(indole) alkaloids.1 These
compounds, as well as their unnatural analogs, have shown
promise as leads for the development of novel therapeutics.
Although many bis(indole) alkaloids have been found in
nature, relatively few have been discovered in marine environ-
ments.2 Of those, a family of compounds isolated from
Dragmacidon sp. (i.e., the dragmacidins) have received con-
siderable attention from the scientific community over the past
decade because of their broad range of biological activity and
complex and unique structures (1–7, Fig. 1).3,4 The four
dragmacidins initially identified (1–4) contain a piperazine
linker and display modest antifungal, antiviral and cytotoxic
activities.3a–c However, our interest in these natural products
was piqued by the more complex pyrazinone-containing family
members, dragmacidins D (5), E (6), and F (7).3d–g The striking
array of functionality in these stunning molecules (i.e., the
pyrazinone, aminoimidazole, aryl bromide, the free phenol in
5), in addition to the architectural arrangement of the
polyheterocyclic core structures, posed a variety of synthetic
challenges.
Preliminary studies suggest that the pyrazinone dragmaci-
dins (i.e., 5–7) are important compounds from a biological
standpoint, thereby rendering them attractive targets for total
synthesis. In particular, dragmacidins D (5) and F (7) have
been studied most extensively. In addition to displaying anti-
inflammatory activity, cytotoxicity and phosphatase inhibi-
tion,3d,3e 5 has shown selectivity as an inhibitor of neural nitric
oxide synthase.5 Molecules possessing this bioactivity are
thought to be excellent leads for the discovery of novel drugs
that target neurodegenerative disorders such as Alzheimer’s,
Parkinson’s and Huntington’s diseases.6 Furthermore, drag-
macidin F (7) is reported to exhibit in vitro antiviral activity
against herpes simplex virus (HSV-I; EC50 = 95.8 mM) and
human immunodeficiency virus (HIV-I; EC50 = 0.91 mM).
3f
Given the difficulty in obtaining dragmacidins from marine
environments, as well as the low abundance of some of these
compounds from natural sources, we reasoned that synthetic
routes to the pyrazinone dragmacidins (5–7) and their analogs
could facilitate advanced biological studies.
In this review, we highlight recent synthetic studies from our
laboratory that has led to the development of a unified strategy
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for the preparation of several dragmacidin alkaloids. The
success of these efforts can largely be attributed to the power
of transition metal chemistry in modern organic synthesis.
The design of a unified strategy
While the biosynthesis of the dragmacidins has not been
studied in detail, dragmacidins D, E and F are likely
biosynthetically related. Of the possible biosynthetic scenarios,
most probable is that dragmacidins E (6) and F (7) are derived
by cyclization of either dragmacidin D (5) or a closely related
congener (Fig. 2). For example, dragmacidins D and E are
structural isomers that differ by a single C–C bond. In nature,
it is likely that a Friedel–Crafts cyclization between the
pyrazinone and aminoimidazole groups of dragmacidin D
occurs in order to construct the seven-membered ring of
dragmacidin E (i.e., 5A6). Dragmacidins D (5) and F (7) also
differ in connectivity by one C–C bond; however, in this case,
there is also a difference in oxidation state between the two
natural products. Thus, oxidative dearomatization with con-
comitant cyclization could facilitate the formation of the
unique polycyclic framework present in dragmacidin F (i.e.,
5 A 7). Related oxidation pathways for tryptophan derivatives
have been observed in nature.7 Finally, it is plausible that
dragmacidin D and hence the core of all the dragmacidins are
derived by the biosynthetic dimerization of two functionalized
tryptophan derivatives.
The identification that there was a clear biosynthetic
relationship between the dragmacidins led us to consider the
design of a unified synthetic strategy that would take
advantage of the similar functionality groupings and con-
nectivities of key skeletal components. While there were clear
differences among the members of the pyrazinone family, the
general feature that the molecules were constructed of a core
pyrazinone flanked by two different heterocycles was of
paramount importance in developing our strategy.
The total synthesis of dragmacidin D
Having selected the pyrazinone-containing dragmacidins,
namely, dragmacidins D (5), E (6) and F (7), as formidable
synthetic targets for our laboratory we first chose to pursue the
total synthesis of dragmacidin D (5),3d,e,8 predominantly
because it appeared to be the simplest of the pyrazinone-
containing family members. Learning how to selectively build
the skeleton of dragmacidin D, as well as construct and reveal
all of the functionality present, was a major challenge to our
laboratory. Moreover, we hoped to develop a strategy for the
preparation of dragmacidin D (5) that would be amenable to
the synthesis of the other complex dragmacidin natural
products.
When considering the structure of dragmacidin D (5),
several synthetic challenges become apparent. Dragmacidin D
possesses a total of seven nitrogen atoms, three of which are
incorporated in the aminoimidazole moiety, while two are
within the pyrazinone core. The compound contains an
unusual bis(indole) architecture featuring a 3,4,7-trisubstituted
indole and a 3,6-disubstituted indole. Access to both of these
indole substitution patterns is known to be synthetically
challenging.9 It was predicted that dragmacidin D (5), as well
as many of its synthetic precursors, would be highly polar,
extremely reactive and perhaps difficult to handle in a
laboratory setting.
Two retrosynthetic strategies for the synthesis of dragma-
cidin D (5) are presented in Scheme 1. We targeted 5 through
Fig. 2 Unified biosynthetic relationship. Scheme 1 Retrosynthesis of dragmacidin D (5).
Fig. 1 The dragmacidin alkaloids.
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two complementary routes: (i) a classical cyclocondensation
approach10 and (ii) a more modern transition metal-mediated
cross-coupling approach.11 In approach i, the pyrazinone
system would be constructed through the linkage of two
functionalized indole units (8 + 9), while in route ii, the
dragmacidin core was envisioned to arise by a stepwise three-
component coupling sequence (10 + 11 + 12).
In 2000, our laboratory began working on the two
approaches outlined above. Initially we investigated the
viability of the cyclocondensation strategy (i). Although we
were able to prepare simple bis(indole) pyrazinone model
systems, attempts to utilize more advanced fragments were
unsuccessful and we quickly redirected our attention to the
transition metal-catalyzed cross-coupling route (ii). To carry
out this plan successfully, it seemed that a more detailed
strategy was needed, involving not only the exact order of the
coupling reactions, but also the specific identity of each
substrate involved. The judicious selection of halides, metals
and protecting groups would be crucial. We thus carried out a
series of experiments that would delineate suitable conditions
for cross-coupling.
After examining a number of model systems, we began to
identify appropriate substitution patterns for building blocks
10, 11 and 12 (Fig. 3). It was immediately clear that the use of
Pd(0)-catalyzed Suzuki couplings would be favorable given the
abundant precedence for these cross-couplings in heterocycle
chemistry.12 Thus, boron substituents were employed as the
nucleophilic component for both indole substrates (10 # 13
and 12 # 15). In addition, the protecting groups for the
indoles were chosen in a manner that optimized orthogonality
with respect to deprotection, thus facilitating control during
late-stage manipulations. In particular, the N-protecting
groups were carefully selected.13 The SEM group of 13 was
considered ideal due to its marked stability and electron-
donating nature,14 while the Ts group of 15 was preferred
mainly because of its success in model system studies. Perhaps
the most important decision was the selection of halogens X1
and X2 of generic pyrazine 11. In order to keep 15 in tact
through the cross-coupling sequence, both X1 and X2 would
have to be more reactive to Pd(0) than the 6-bromoindole
functionality. Ultimately, bromoiodopyrazine 14 was chosen
as the key synthetic fragment that would allow for this
selectivity.15 We then developed rapid syntheses of the three
essential pieces (13, 14 and 15) in a relatively straightforward
manner.
With the appropriate fragments in hand (13, 14 and 15), the
critical three-component coupling reaction sequence was
explored. Suzuki coupling of dihalopyrazine 14 and indole
15 proceeded selectively to afford the coupled indolylpyrazine
16 (Scheme 2). In the second Suzuki coupling of dibromide 16
with boronic ester 13, we were delighted to find that the
desired bis(indole)pyrazine 17 formed in good yield and with
complete selectivity for coupling of the pyrazinyl bromide in
the presence of the indolyl bromide. Precise temperature
control was critical for the success of both coupling reactions
(23 and 50 uC, respectively). Importantly, the selectivity of the
second Suzuki reaction depended not only on temperature, but
also on the exact identity of each coupling substrate. In fact,
varying protective groups on the indole nitrogen in 15 had a
dramatic effect on halide reactivity, as competitive coupling of
the indolyl bromide occurred when electron-donating
N-protective groups were employed.
In our initial endgame approach, we chose to first attempt
installation of the aminoimidazole unit and proceeded by
elaborating 17 to carboxylic acid 18 (Scheme 3). Subsequent
conversion of 18 to bromoketone 19 was accomplished by an
Fig. 3 Identification of cross-coupling fragments.
Scheme 2 Halogen-selective Suzuki couplings to access 17.
Scheme 3 End-game strategy 1.
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Arndt–Eistert-type homologation, followed by treatment with
aqueous HBr. The extreme sensitivity of the intermediate acid
chloride was particularly troublesome and required that the
diazomethane used in the reaction sequence be dried thor-
oughly over both potassium hydroxide and sodium metal
immediately before use.16 In addition, chemical yields for this
homologation varied to a large extent and caused substantial
material throughput problems. Nonetheless, exposure of 19 to
ammonia afforded an intermediate aminoketone which, in
turn, underwent facile condensation with cyanamide to
produce the desired aminoimidazole product (20).17 At this
point, all that remained in order to complete the total synthesis
of dragmacidin D (5) was the removal of the four protective
groups from 20. Despite several months of experimentation,
our efforts to complete the total synthesis of 5 were
accompanied by decomposition of the aminoimidazole moiety,
which was exceptionally unstable to the conditions (acidic,
basic or reductive) needed to remove the protective groups that
we had strategically chosen (vide supra).
The possibility of installing the aminoimidazole as the last
step of the total synthesis, after the full deprotection of a late-
stage intermediate, was explored next. In addition, we sought
an alternative one-carbon homologation reaction in place of
the unreliable and experimentally tedious Arndt–Eistert
sequence. After extensive experimentation, a solution to our
problems was discovered. Namely, we found that nitro-
methane addition18 to aldehyde 21 and subsequent oxidation
produced 22 in high yield (Scheme 4). Nitroketone 22, in turn,
was a suitable intermediate for the removal of the indole
nitrogen protective groups. Deoxygenated ethanolic potassium
hydroxide facilitated removal of the N-tosyl group,19 while
lithium tetrafluoroborate followed by aqueous sodium hydro-
xide effected complete hydrolysis of the SEM group (22 A 23).
Reduction of nitroketone 23 with stannous chloride,20 then
cleavage of the benzyl and methyl ethers with iodotrimethylsi-
lane revealed fully deprotected aminoketone 24.21,22 Final
installation of the aminoimidazolium unit occurred by treat-
ment of 24 with cyanamide followed by trifluoroacetic acid
workup to produce dragmacidin D (5) in 86% yield. This effort
stands as the only completed total synthesis of dragmacidin D
to date.23–25
The total synthesis of dragmacidin F
Having developed a strategy to construct the bis(indole)pyr-
azinone core of dragmacidin D (5), we set out to apply our
Pd(0) halogen-selective Suzuki coupling methodology to the
synthesis of related natural products. We hypothesized that
our approach could be amenable to the preparation of the
antiviral agent dragmacidin F,3f,g which is perhaps the most
challenging target of the dragmacidin natural products.
Dragmacidin F shares a number of structural features with
dragmacidin D, namely, an aminoimidazolium fragment, a
differentially substituted pyrazinone and a 6-bromoindole
unit. However, rather than containing two indole functional-
ities, dragmacidin F possesses one indole, in addition to a
pyrrole appended [3.3.1] bicycle. It is important to note that at
the time of our synthetic effort, the absolute stereochemistry of
natural dragmacidin F was not know; thus, the absolute
stereochemistry of our target was chosen arbitrarily.
Our retrosynthetic analysis for dragmacidin F is shown in
Scheme 5. We reasoned that the aminoimidazole would best be
incorporated at a late stage in the synthesis. The carbon
scaffold of 7, could be assembled via a series of halogen-
selective Suzuki cross coupling reactions of 25, 14 and 15 in an
analogous manner to the dragmacidin D sequence. Since
pyrazine 14 and boronic acid 15 were readily accessible, our
success would depend highly on the ability to prepare
pyrroloboronic ester 25. We envisioned deriving this key
coupling fragment from parent bicycle 26 which, in turn,
would arise via an intramolecular Pd-mediated oxidative
carbocyclization reaction of acyl pyrrole 27.26 This latter
transformation was extremely appealing to us given our
laboratory’s interest in Pd oxidation chemistry.27 Although
we had previously cyclized indoles and electron rich aromatics
in the presence of Pd(II), examples of pyrroles undergoing the
Scheme 4 The total synthesis of dragmacidin D (5). Scheme 5 Retrosynthesis of dragmacidin F (7).
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analogous carbocyclization were not known in the literature or
our own laboratory.28 In the final retrosynthetic disconnec-
tion, pyrrole 27 would be accessible from (2)-quinic acid
(28),29 a commercially available enantiopure starting material.
Our first task was to devise an efficient route to 27 beginning
from (2)-quinic acid (28, Scheme 6). Lactone 29 could be
obtained in four simple steps and then reductively isomerized
to acid 30 upon treatment with Pd/C in MeOH at 0 uC in the
presence of H2.
30 Notably, this transformation proceeded in
essentially quantitative yield and allowed for the preparation
of multigram quantities of 30 in a facile manner. More
importantly, acid 30 could be converted to cyclization
substrate 27 via a two-step protocol involving Weinreb amide
formation30,31 and displacement by 2-lithio-1-SEM-pyrrole
(32).31
With acyl pyrrole 27 in hand, we turned our attention to the
key Pd(II)-mediated cyclization reaction (Scheme 7). After
substantial experimentation, we found that [3.3.1] bicycle 26
could be formed upon exposure of 27 to a Pd(OAc)2/DMSO
system.32 Under our optimized reaction protocol, bicycle 26
was isolated in 74% yield. Notably, this transformation
(27A26) results in functionalization of the electronically
deactivated and sterically congested C(3) position of acyl
pyrrole 27.33,34 Furthermore, undesired [3.2.2] bicycle 33 was
not observed under these Pd(II) conditions, although 33
formed in substantial quantities in the analogous Heck
reaction.35,36
Our next goal was to construct the carbon skeleton of the
natural product (Scheme 8). Following a straightforward four
step sequence, bicycle 26 was elaborated to the crucial boronic
ester fragment (25). By analogy to our dragmacidin D studies,
we were pleased to find that upon treatment of 25 with
bromopyrazine 16 under our standard Suzuki coupling
conditions, the desired C–C bond formation took place to
afford the fully coupled product (34) in 77% yield.
Importantly, the indolyl bromide moiety was maintained
under these reaction conditions. Following cleavage of the
silyl ether and subsequent oxidation, we arrived at ketone 35.
We anticipated that the presence of an amino group a to the
ketone would allow for eventual introduction of the aminoi-
midazole moiety, as was the case in our synthesis of
dragmacidin D (5). Thus, we focused our efforts on preparing
compounds related to 36.
Our first efforts to functionalize the ketone a-position
involved a nitration strategy to access a compound analogous
to an intermediate employed in the dragmacidin D synthesis.37
Unfortunately, in all of these cases, formation of the desired
nitroketone product was not observed. We switched to a
strategy whereby the a nitrogen substituent could be installed
via nucleophilic displacement of an a bromide. Thus,
bromoketone 37 was prepared from ketone 35 as a single
diastereomer via a silyl enol ether intermediate (Scheme 9).38
Much to our surprise, bromoketone 37 was extremely prone to
base promoted rearrangements when treated with nitrogenous
nucleophiles. For example, upon exposure of bromoketone 37
to NaN3, azidoketone 38 formed as the major product.
Furthermore, simply reacting bromide 37 with a basic fluoride
Scheme 6 Synthesis of cyclization substrate 27.
Scheme 7 Pd(II)-Mediated oxidative carbocyclization.
Scheme 8 Synthesis of the carbon scaffold of dragmacidin F.
Scheme 9 End-game studies and unexpected rearrangements.
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anion source (TBAF in THF) led to Favorskii rearrangement
product 39.39 The use of basic amine nucleophiles also yielded
related Favorskii products.
A number of other options for installing the a-aminoketone,
including enol silane oxidative azide formation and aminohy-
droxylation, were attempted as well, but were met without
success. As our options diminished, we considered an
alternative plan that would rely on the use of a Neber
rearrangement to install the necessary nitrogen substitu-
ent.40,41 In this scenario, an activated oxime derivative would
undergo alkoxide-promoted rearrangement to furnish an
a-aminoketone. Although this transformation is relatively
uncommon and typically hampered by competitive Beckman
rearrangement pathways, we elaborated ketone 35 to tosyl
oxime 40 via known protocols (Scheme 10). In our initial
experiments, exposure of substrate 40 to aqueous KOH in
ethanol led to the formation of Neber rearrangement products.
After optimization, we uncovered a simple two-pot protocol to
access deprotected a-aminoketone 44 as a single regio- and
stereochemical isomer in excellent yield, as follows: (i) reaction
of tosyloxime 40 with KOH in ethanol facilitates cleavage of
the indole tosyl group and likely promotes formation of azirine
41 which, in turn, is attacked by ethoxide42 to afford
ethoxyaziridine 42; (ii) subsequent quenching with HCl results
in hydrolysis of the ethoxyaziridine with concomitant partial
cleavage of the SEM protective group to furnish aminoketone
43;43 (iii) treatment of hemiaminal 43 with K2CO3 removes the
remaining portion of the SEM group, thus giving rise to the
deprotected product (44).22,44 To the best of our knowledge,
this is the first example of a successful Neber rearrangement in
the context of natural product synthesis.45,46
Having installed the a-aminoketone and removed the
N-protective groups, completion of the total synthesis of
dragmacidin F proceeded smoothly. In order to unveil the
masked pyrazinone functionality, Neber rearrangement pro-
duct 44 was treated with TMSI at 60 uC (Scheme 11).13
Fortuitously, both the pyrazinone and the tertiary alcohol
functionalities were revealed simultaneously (44 A 45). In the
final step of the synthesis, the penultimate aminoketone (45)
was subjected to cyanamide and aqueous NaOH to produce
enantiopure dragmacidin F (7).47 Our efficient and enantio-
specific route allows access to 7 in 7.8% overall yield in just
21 steps from (2)-quinic acid (28).48
As mentioned earlier, the absolute stereochemistry of
natural dragmacidin F was not known when we began our
total synthesis. Although our synthetic sample was identical to
natural dragmacidin F3f by most analytical techniques
(1H NMR, 13C NMR, IR, UV, HPLC), the sign of optical
rotation differed. Thus, we had prepared the unnatural (+)
enantiomer of dragmacidin F. However, our synthesis begin-
ning from (2)-quinic acid (28) established, for the first time,
the absolute configuration of natural dragmacidin F (7) to be
(40S, 60S, 6-S) as shown in Fig. 4.49 In addition, it has been
proposed that dragmacidins D, E and F are biosynthetically
related. Based on this notion, it is likely that the absolute
stereochemical configurations of natural dragmacidins D (5)
and E (6) are (6-S) and (5-R, 6-S), respectively.
The total synthesis of nat-(2)-dragmacidin F
We next pursued the total synthesis of the natural (2)
enantiomer of dragmacidin F (7). Having developed a route
to (+)-dragmacidin F (7) from (2)-quinic acid (28), we
reasoned that the simplest solution to accessing the natural
Scheme 10 Neber rearrangement/deprotection sequence.
Scheme 11 The total synthesis of (+)-dragmacidin F (7).
Fig. 4 The absolute stereochemistry of pyrazinone dragmacidins.
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enantiomer of dragmacidin F (7) would be to employ (+)-
quinic acid (28) as a starting material. Unfortunately, the (+)-
enantiomer of 28 is not easily accessible either commercially or
via synthetic means.50 It seemed plausible, however, that the
readily available (2) enantiomer of quinic acid (28) could be
used to access both enantiomers of dragmacidin F (7).51
Despite its widespread use in natural product synthesis, (2)-
quinic acid (28) has rarely been used in an enantiodivergent
sense.
Our enantiodivergent strategy to prepare both enantiomers
of dragmacidin F from a single enantiomer of quinic acid is
shown in Scheme 12. In order to complete the total synthesis of
(+)-dragmacidin F (7), a (2)-quinic acid derivative (e.g., 47)
had been subjected to a reductive isomerization reaction that
proceeded with loss of the C(5) leaving group. The product of
this reaction was elaborated to acyl pyrrole 27 which, in turn,
was used to prepare (+)-7. We reasoned that a similar
reduction of 47 that occurred with removal of the C(3)
substituent could be used to access cyclohexene 46 en route to
(2)-nat-dragmacidin F (7). Since acyl pyrrole species 46 and 27
are diastereomeric, it was also possible that transformations
that were used to convert 27 to (+)-7 would not be applicable
to the conversion of 46 to (2)-7. Nonetheless, we focused our
attention on developing a reductive isomerization substrate of
type 47 that would lead to cyclohexene 46.
In order to select the appropriate reductive isomerization
substrate needed to access (2)-7, a close examination of the
analogous reaction used in our (+)-dragmacidin F (7) synthesis
was necessary. It seemed that the success of the reductive
isomerization of lactone 29 to cyclohexene 30 was largely the
result of the excellent carboxylate leaving group at C(5) of 29
being restricted to an axial orientation, thereby facilitating its
elimination (Scheme 13). Therefore, in designing our new
substrate, we envisioned that the tertiary alcohol could be used
to lock the C(3) oxygen substituent in an axial disposition in
the form of a carbonate leaving group in order to facilitate its
elimination (i.e., 48 A 49).30 Thus, pyrrolocarbonate 50 was
chosen as a suitable (2)-quinic acid derivative needed for our
reductive isomerization studies and became our target of
interest.
Developing a synthesis of carbonate 50 was relatively
straightforward. (2)-Quinic acid derivative 29, which was
used in our total synthesis of (+)-7, was first treated with
2-lithio-SEM-pyrrole (32, Scheme 14). Subsequent TBS
protection afforded bis(silyl ether) 51 in good yield. This
pseudo-C2-symmetric
52 compound then underwent rapid
diastereoselective mono-desilylation upon treatment with
TBAF in THF to produce the syn 1,3-diol 52.53 Importantly,
this desymmetrization proceeded with complete selectivity and
allowed us to efficiently differentiate the C(3) and C(5)
positions of the cyclohexyl moiety. Diol 52 was smoothly
converted to bicyclic carbonate 50 in the presence of CDI,
effectively restricting the C(3) substituent to an axial disposi-
tion. In the key reductive isomerization reaction, exposure of
carbonate 50 to our optimal reaction conditions (2 mol% Pd/
C, H2, MeOH, 0 uC) led to the selective formation of the
desired cyclization substrate (46) in 90% yield.54
With cyclization substrate 46 in hand, we focused our
attention on the key Pd(II)-mediated carbocyclization to
construct the [3.3.1] bicycle of the natural product
(Scheme 15). Despite the degree of steric hindrance imposed
upon the C(3) a face by the bulky C(5) silyl ether group
Scheme 12 An enantiodivergent strategy for the preparation of (+)-
and (2)-dragmacidin F (7).
Scheme 13 Rational design of reductive isomerization substrate 50.
Scheme 14 Elaboration of (2)-quinic acid to 46.
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positioned syn to the acyl pyrrole, exposure of 46 to our
optimal cyclization conditions resulted in formation of the
desired product (53). Following protection of the tertiary
alcohol, [3.3.1] bicycle 54 was obtained in 68% yield for the
two-step process.
After elaboration of bicycle 54 to boronic ester 55, we were
able to assemble the carbon skeleton of (2)-dragmacidin F
(56) using our halogen-selective Suzuki coupling methods
(Scheme 16). We hoped to convert silyl ether 56 to ketone 35,
the enantiomer of which was employed in our synthesis of (+)-
7. Unfortunately, the selective desilylation of 56 to afford 57
proved to be difficult. This was surprising, since the
diastereomer of 56 employed in the synthesis of (+)-7
participated in the analogous deprotection reaction.
To overcome this roadblock, we pursued strategies whereby
the TBS ether could be cleaved at an earlier stage in the
synthesis. In a critical reaction, the sterically less crowded TBS
ether of olefinic substrate 53 underwent smooth and selective
cleavage upon treatment with TBAF in THF to afford allylic
alcohol 58 (Scheme 17). Upon exposure of alcohol 58 to
Brown’s cationic rhodium catalyst Rh(nbd)(dppb)BF4
55 and
H2, ketone 59 formed directly as a single diastereomer in 98%
yield. Regioselective bromination and low-temperature meta-
lation of the pyrrole in the presence of two ketones gave rise to
boronic ester 60. Subsequent halogen-selective cross-coupling
of 60 with dibromide 16 afforded the desired Suzuki adduct
(2)-35 (89% yield). Finally, Suzuki product (2)-35 was
converted to (2)-dragmacidin F ((2)-7) via our previously
described six-step protocol (vide supra). Synthetic and natural
(2)-73f were spectroscopically identical, including the sign of
optical rotation (natural (2)-7: [a]25D 2159u (c 0.4, MeOH);
synthetic (2)-7: [a]23D 2148u (c 0.2, MeOH)). Our highly
efficient syntheses provide (+)-7 in 7.8% overall yield and (2)-
7 in 9.3% overall yield beginning from 28. Moreover, this work
represents the first and, to date, only total synthesis of the
antiviral agent dragmacidin F.56
The pyrazine dragmacidins: the formal total
synthesis of dragmacidins A, B and trans-
dragmacidin C
Having established that halogen-selective Suzuki couplings are
a powerful method for constructing the carbon skeleton of the
pyrazinone-containing dragmacidins, we hypothesized that a
similar strategy could be used to access the piperazine
dragmacidins. More specifically, our retrosynthesis for drag-
macidins A (2), B (3)3b and trans-dragmacidin C (4)3c is shown
in Scheme 18. Based on the work of Horne and co-workers,4d,g
we envisioned that each of the bis(indole) alkaloids could be
accessed from unsaturated pyrazine 61 in a single step.
Pyrazine 61, in turn, would be obtained from two halogen-
selective Suzuki cross-coupling reactions of boronate 62 with a
dihalogenated pyrazine (63).
In order to probe the limits of our halogen-selective
Suzuki cross-coupling methodology, we chose to use known
dibromide 6457 as the critical pyrazine fragment (Scheme 19).
Scheme 15 Construction of [3.3.1] bicycle 54.
Scheme 16 End-game strategy 1.
Scheme 17 The total synthesis of (2)-dragmacidin F (7).
Scheme 18 Retrosynthesis of piperazine dragmacidins.
3776 | Chem. Commun., 2006, 3769–3779 This journal is  The Royal Society of Chemistry 2006
In a one-pot, four-step transformation, an excess of
6-bromoindolylboronic acid (15) was exposed to dibromopyr-
azine 64 under our standard cross-coupling conditions.
Following quenching with KOH/ethanol, the deprotected
pyrazine product (61) was obtained in 54% yield. Notably,
although four bromides were introduced in the reaction
mixture, only the two pyrazinyl bromides were reactive in
the presence of Pd(0) at 50 uC. This rapid synthesis of
bis(indole)pyrazine 61 constitutes a formal total synthesis of
dragmacidins A (2), B (3) and trans-dragmacidin C
(4).4d,4g,58,59 We have also used a similar approach to prepare
members of a related family of natural products, the
dihydrohamacanthins.60
Conclusion
In summary, we have developed a highly convergent strategy
to assemble the dragmacidin natural products. Our approach
involves the use of sequential Pd(0)-catalyzed halogen-selective
Suzuki couplings to construct the carbon skeletons of these
important molecules. Ultimately, this method has been used to
achieve the total syntheses of dragmacidins A, B, C and D, in
addition to both enantiomers of dragmacidin F. Our work
involving dragmacidin D (5) and (+)- and (2)-dragmacidin F
(7) remain the only completed total syntheses of the
pyrazinone-containing dragmacidins, to date. The success of
this work can largely be attributed to the utility of transition
metal chemistry in modern organic synthesis, where we have
used Pd-mediated cross-couplings, reductive isomerizations
and oxidative carbocyclizations as key steps in our total
syntheses. Biological evaluation of synthetic dragmacidins and
their analogs is currently in progress.
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